Mankind Pharma has announced its consolidated financial results for the third quarter, showing strong revenue growth alongside improved profitability and operational efficiency. The pharmaceutical company demonstrated robust year-on-year performance across key financial metrics while falling short of analyst projections on the profit front.

Financial Performance Overview

The company reported consolidated revenue of ₹36 billion for Q3, representing significant growth from ₹32 billion in the corresponding quarter of the previous year. This revenue expansion reflects the company's continued market presence and business momentum during the quarter.

The company's consolidated net profit for Q3 reached ₹4.10 billion, marking an increase from the ₹3.80 billion reported in the corresponding quarter of the previous year. This represents positive year-on-year growth in the company's bottom line performance.

EBITDA Performance and Operational Efficiency

Mankind Pharma's operational performance showed improvement with EBITDA reaching ₹9.19 billion in Q3 compared to ₹8.30 billion in the corresponding quarter of the previous year. The company's EBITDA margin also witnessed marginal improvement, rising to 25.76% from 25.70% year-on-year, indicating enhanced operational efficiency and cost management.

Market Expectations vs Actual Results

Despite the year-on-year improvement, Mankind Pharma's Q3 consolidated net profit of ₹4.10 billion fell short of analyst estimates, which had projected earnings of ₹5.10 billion for the quarter. This gap between expected and actual performance represents a significant variance from market consensus.

The pharmaceutical sector continues to face various operational and market dynamics that influence quarterly performance. Mankind Pharma's results reflect the company's ability to maintain growth momentum while navigating industry challenges and market conditions during the quarter.

Mankind Pharma has announced its quarterly investor conference call to discuss Q3 and 9M FY26 financial results. The pharmaceutical company informed stock exchanges about the scheduled earnings call on January 16, 2026, in compliance with SEBI regulations.

Earnings Call Schedule

The investor conference call is scheduled for February 3, 2026, and will run for one hour from 6:00 PM to 7:00 PM IST. The call aims to provide insights into the company's business performance and financial results for the third quarter and nine-month period of FY26.

Dial-in Information

The company has provided comprehensive access options for investors and analysts to participate in the earnings call. Multiple dial-in numbers are available to accommodate both domestic and international participants.

Participants can pre-register for the call to avoid wait times and dial in directly without waiting for operator assistance.

Management Participation

The earnings call will feature comprehensive representation from Mankind Pharma's senior leadership team. Seven key executives will participate to provide detailed insights into the company's performance and address investor queries.

Senior Management Participants:

• Mr. Rajeev Juneja – Vice Chairman & Managing Director
• Mr. Sheetal Arora – Chief Executive Officer & Whole Time Director
• Mr. Arjun Juneja - Chief Operating Officer
• Mr. Sudipta Roy – Senior President – Sales & Marketing
• Mr. Ashutosh Dhawan – Global Chief Financial Officer
• Mr. Prakash Agarwal – President (Strategy)
• Mr. Abhishek Agarwal – Head - Investor Relations & AVP - Strategy

Contact Information

For additional details regarding the earnings call, investors can reach out through multiple channels. The company has provided both internal and external contact points for investor relations support.

The announcement was formally communicated to BSE Limited and National Stock Exchange of India Limited under Regulation 30 and 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Hitesh Kumar Jain signed the regulatory filing, and the details are also available on the company's official website at www.mankindpharma.com .